Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus DEXACEN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus DEXACEN 4.
ASMANEX HFA vs DEXACEN-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid